Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Agmatine and Methamphetamine

supplement:

Agmatine

Research Papers that Mention the Interaction

All injections were done intraperitoneally and agmatine was administrated 10 min before METH treatment.
Also, molecular results revealed that METH (2 mg/kg) markedly decreased hippocampal CaMKII-α gene expression while agmatine (10 mg/kg) co-adminstration prevented it.
Taken together, the results propose that agmatine may provide a potential therapy for learning and memory deficits induced by METH.
The aim of this study was to determine if agmatine can decrease the impairment effect of METH on memory and hippocampal CaMKII-α gene expression, a gene that plays a major role in memory.
While Agmatine with a higher dose (10 mg/kg) significantly decreased impairment effect of METH (2 mg/kg) on PAL and memory.
Physiology & Behavior  •  2018  |  View Paper
Agmatine (10–100 mg/kg) did not substitute for methamphetamine, but significantly attenuated the stimulus effects of methamphetamine , leading to a maximum of a 3.5-fold rightward shift.
Agmatine (10–32 mg/kg) pretreatment significantly attenuated the hyperthermic effect of methamphetamine.
Agmatine is a naturally occurring cationic polyamine that has previously been shown to attenuate the rewarding and psychomotor-sensitizing effects of methamphetamine.
Behavioural pharmacology  •  2016  |  View Paper
Agmatine pretreatment alone had no effects on locomotion or stereotypy, but it produced a dose-dependent attenuation of locomotion and the total incidence of stereotyped behavior induced by a low dose of METH (5 mg/kg).
Agmatine pretreatment therefore appears to produce a rightward shift in the dose–response curve for METH.
However, the nature of stereotypy induced by this dose of METH was substantially altered; agmatine pretreatment significantly reduced stereotyped biting but significantly increased stereotyped sniffing and persistent locomotion.
Behavioural pharmacology  •  2014  |  View Paper
Agmatine, at doses that did not produce place preference or aversion (10-32mg/kg), significantly decreased the development of methamphetamine-induced place preference when agmatine was administered in combination with methamphetamine during place conditioning.
Together, these data suggests that agmatine attenuates the rewarding effects of methamphetamine and may be able to modulate the abuse liability of methamphetamine.
European journal of pharmacology  •  2012  |  View Paper
Withdrawal was inhibited similarly when planarians coexposed to agmatine (100 μM) plus methamphetamine (10 μM), WIN 55,212‐2 (10 μM), or U‐50,488H (10 μM) were tested in water.
Synapse  •  2008  |  View Paper